Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Myelodysplastic Syndromes 16Hodgkin Disease 13Lymphoma, Non-Hodgkin 11Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Leukemia, Biphenotypic, Acute 8Leukemia 8Burkitt Lymphoma 7Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neuroblastoma 5Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hematologic Neoplasms 5Triple Negative Breast Neoplasms 4Sarcoma 4Rhabdomyosarcoma 4Medulloblastoma 4Lymphoma, Follicular 4Anemia, Refractory, with Excess of Blasts 4Leukemia, Myelomonocytic, Chronic 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

Vincristine 1Radiotherapy 1Irinotecan 1Ifosfamide 1Filgrastim 1Etoposide 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant mesenchymal tumor × Filgrastim × 1 year × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡